Revenue ($USD) : $313,789,000
R&D spend : $38,879,000
Employees : 1,300
Fiscal year end : 12/31/2022
CEO : Patrick Mackin

Artivion (formerly known as CryoLife) develops devices for cardiac and vascular surgeons who specialize in treating patients with aortic diseases. The company’s devices and implantable tissues are used in aortic repair procedures.

In May, the company won FDA approval for its PerClot absorbable hemostatic system, which is used to control bleeding in open and laparoscopic surgical procedures. Baxter paid the company a $14.3 million milestone payment following the regulatory win. –BB